BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18062748)

  • 1. Biomarkers in clear cell renal cell carcinoma.
    George S; Bukowski RM
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1737-47. PubMed ID: 18062748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
    Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
    J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic markers in renal cell carcinoma.
    Ljungberg B
    Curr Opin Urol; 2007 Sep; 17(5):303-8. PubMed ID: 17762621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
    Klatte T; Seligson DB; LaRochelle J; Shuch B; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):894-900. PubMed ID: 19240241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic biomarkers in renal cell carcinoma.
    Jiang Z
    Expert Rev Mol Diagn; 2007 May; 7(3):293-307. PubMed ID: 17489736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic molecular markers in renal cell carcinoma.
    Tunuguntla HS; Jorda M
    J Urol; 2008 Jun; 179(6):2096-102. PubMed ID: 18423738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.
    Minervini A; Di Cristofano C; Gacci M; Serni S; Menicagli M; Lanciotti M; Salinitri G; Rocca CD; Lapini A; Nesi G; Bevilacqua G; Minervini R; Carini M
    J Urol; 2008 Oct; 180(4):1284-9. PubMed ID: 18707725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cell carcinoma: basic biology and clinical behavior.
    Franklin JR; Figlin R; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):208-15. PubMed ID: 8946619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.
    Peccatori J; Barkholt L; Demirer T; Sormani MP; Bruzzi P; Ciceri F; Zambelli A; Da Prada GA; Pedrazzoli P; Siena S; Massenkeil G; Martino R; Lenhoff S; Corradini P; Rosti G; Ringden O; Bregni M; Niederwieser D;
    Cancer; 2005 Nov; 104(10):2099-103. PubMed ID: 16220555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value.
    Liang YX; He HC; Han ZD; Bi XC; Dai QS; Ye YK; Qin WJ; Zeng GH; Zhu G; Xu CL; Zhong WD
    Cancer Invest; 2009 Aug; 27(7):788-93. PubMed ID: 19548138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal cell carcinoma and proteomics.
    Sandim V; Pereira DA; Ornellas AA; Alves G
    Urol Int; 2010; 84(4):373-7. PubMed ID: 20224258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability.
    Eichelberg C; Junker K; Ljungberg B; Moch H
    Eur Urol; 2009 Apr; 55(4):851-63. PubMed ID: 19155123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.
    Lam JS; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6304S-9S. PubMed ID: 15448022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials.
    Lam JS; Pantuck AJ; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):703s-708s. PubMed ID: 17255297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.
    Sun M; Shariat SF; Cheng C; Ficarra V; Murai M; Oudard S; Pantuck AJ; Zigeuner R; Karakiewicz PI
    Eur Urol; 2011 Oct; 60(4):644-61. PubMed ID: 21741163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
    Mizuno R; Oya M
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.